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biochemical/molecular epidemiological studies. Though the area of neurotoxicology has received
much attention in the past several years, it still lags behind with regard to the development of
biomarkers, particularly those of health effects and susceptibility. This review discusses several
aspects of biomarker research as it relates to neurotoxic compounds and focuses on selected
agents (organophosphorus insecticides, styrene, n-hexane, carbon disulfide, acrylamide), which
have been the subject of a number of investigations in animals and humans. While traditional
biomonitoring approaches and novel techniques (e.g., hemoglobin adducts) provide several
measurements for monitoring exposure to neurotoxic chemicals, potential markers of genetic
susceptibility have been seldom investigated in a neurotoxicology context. Furthermore, the
complexity of the nervous system, together with the multiplicity of end points and the limited
knowledge of the exact mechanism(s) of action of neurotoxicants, has led to only limited
advancements in the development of biomarkers for neurotoxic effects. Significant progress in
this area will depend upon an increased understanding of the cellular, biochemical, and molecular
targets directly involved in neurotoxicity. Environ Health Perspect 104(Suppl 1):55-67 (1996)
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Introduction
The field ofbiomarkers has been the object
ofincreased interest in the past few years,
as evidenced by the large number ofpubli-
cations, workshops, and symposia devoted
to this topic (1-8). The term biomarker
may be overused, as it is utilized in refer-
ence to different end points oftoxicity in
animals or humans. For example, the pres-
ence ofchloracne may be considered a bio-
marker ofexposure to and ahealth effect of
dioxinlike compounds, and behavioral
alterations in children exposed to lead may
be considered a biomarker of its subtle
neurotoxic effects (9). Additionally, a
number ofbiochemical and morphological
alterations in tissues ofanimals exposed to
toxicants can be considered biomarkers of
target organ toxicities. For the purpose of
this review, the term biomarker is used to
mean biological/biochemical/molecular
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markers, which can be measured by
chemical, biochemical, or molecular bio-
logical techniques. Furthermore, the dis-
cussion will focus on biomarkers that can
be measured in humans and must thus be
present in easily and ethically obtainable
tissues such as'blood or urine.
Biomarkers are usually divided in three
categories: biomarkers of exposure, of
effect, and ofsusceptibility (1). Additional
subdivisions and overlaps between differ-
ent types of biomarkers should also be
considered. For example, within biomark-
ers ofexposure, one could consider either
unchanged or metabolized exogenous
agents or indicators ofbiological effective
dose (10,11). Certain biomarkers ofexpo-
sure, e.g., DNA adducts, may be also
considered as biomarker ofeffect.
This reviewwill focus on biomarkers for
neurotoxicity. Several concepts related to
the development, validation, application,
and use ofbiomarkers will be reviewed only
briefly, as general considerations reported in
several other publications would also apply
to biomarkers for neurotoxicity.
Biomarkers in
Neurotoxicology
Concern for the acute and long-term
effects ofchemicals on the nervous system
has been growing in the past several years
(12,13). The discipline ofneurotoxicology,
which bridges neurosciences and toxicol-
ogy, plays a very important role in the
increasing efforts aimed at understanding
how the brain and the nervous system
work, how to intervene to prevent damage
and restore function, and how environ-
mental factors may play a role in central
nervous system disorders. Since the ner-
vous system controls movement, vision,
hearing, speech, thought, emotions, heart
function, respiration, and many other
physiological functions, it is particularly
vulnerable to toxic substances, and even
minor changes in its structure and function
may have profound neurobiological and
behavioral consequences.
Neurotoxicity is commonly defined as
any permanent or reversible adverse effect
on the structure or function ofthe central
and/or peripheral nervous system by a
biological, chemical, or physical agent.
With regard to biomarkers, the area of
neurotoxicity appears to have been pro-
gressing more slowly than other fields (14).
Indeed, this topic has been addressed by
only a few reviews in the last decade
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(13-20) compared to the large number of
publications devoted, for example, to bio-
markers related to chemical carcinogenesis.
An analysis of the literature, however, sug-
gests that such apparent lack of progress
pertains primarily to the area ofbiomarkers
of effects-rather than to biomarkers of
exposure-where biological indicators for
a large number ofneurotoxicants exist. The
complexity of the nervous system and its
distinctive peculiarities, together with
problems associated with the multiplicity
ofmanifestations ofneurotoxic effects and
the determination ofthe precise targets for
neurotoxicants, are certainly responsible for
this limited advancement. With regard to
biomarkers ofsusceptibility, the paucity of
available examples may be due to the lim-
ited attention that these have received
within neurotoxicology. However, as most
ofsuch markers relate to enzymes involved
in xenobiotic metabolism, it is plausible
that they may play a role in susceptibility
to several neurotoxicants. In this brief
review, I will first analyze biomarkers of
exposure, effect, and susceptibility as they
may apply to neurotoxic compounds. This
will be followed by a more detailed discus-
sion of a selected number of compounds
for which research has been active in the
past few years as examples of possible
research approaches in this area.
Biomarkers ofExposure
It has been stated that "an ideal biomarker
ofexposure is chemical-specific, detectable
in trace quantities, available by noninvasive
techniques, inexpensive to assay and quan-
titatively relatable to prior exposures" (5).
This general concept certainly applies also
to biomarkers of exposure for neurotoxi-
cants. Traditional biomonitoring for expo-
sure to neurotoxic chemicals has relied on
chemical measurements of the compound
of interest and its metabolites in biological
fluids such as blood or urine or in other
accessible tissues such as hair or dentine
pulp. These measurements are still ofgreat
value and, in many instances, are still the
best or only valid and reliable exposure
markers. Examples of these types of bio-
markers abound and can be found in the
area of metals, pesticides, and solvents,
which represent the three major classes of
chemicals that include several neurotoxic
compounds. For metals, blood levels or lev-
els in urine are commonly used. In some
cases, measurements ofmetal concentration
in dentine pulp (e.g., lead) or hair (e.g.,
mercury or arsenic) have proven to be useful
because they reflect prior and/or cumulative
exposure rather than recent exposures (21).
Exposure to neurotoxic solvents is usually
monitored by measuring their concentration
in blood or in breath or by measuring levels
ofmetabolites in urine. Urine metabolites
are also useful for assessing exposure to pes-
ticides. For compounds that are lipophilic
and tend to accumulate in fat tissue (e.g.,
solvents and organochlorine pesticides), fat
biopsy is a way to assess the body burden
due to prior or prolonged exposure.
Binding to macromolecules has proven
useful in monitoring exposure to toxic and
particularly genotoxic compounds because
it reflects the dose ofa certain agent or its
metabolites that escapes detoxification and
reaches its target protein or DNA (22,23).
Recent approaches ofthis strategy to neuro-
toxic compounds have occurred with
n-hexane, carbon disulfide, and acrylamide
and are discussed in following sections. As
red blood cells are long-lived (approxi-
mately 4 months in humans), binding to
hemoglobin is considered a good biomarker
to measure cumulative internal dose due to
repeated exposures. Adducts to albumin can
also be measured. Albumin has a shorter
lifetime in blood (20 to 25 days), and these
measurements will thus reflect more recent
exposure than hemoglobin adducts. One
advantage ofalbumin adducts is that poten-
tial active metabolites can interact with this
protein directly upon their release into the
blood stream without having to penetrate a
cell membrane (5). Thus, albumin adducts
may offer a better, more sensitive marker
for detecting reactive metabolites in blood.
On the other hand, ifadducts are meant to
reflect the levels of neurotoxicant at the
target site, then hemoglobin adducts would
be a more precise biomarker oftarget tissue
dose. Ideally, both measurements could be
carried out and compared; however, no
examples are available for neurotoxic
compounds. The limitation ofadduct mea-
surements as biomarkers ofexposure lies in
the fact that their measurement is often
difficult and time consuming (e.g., when
gas chromatography-mass spectrometry is
employed) and that they are limited to
compounds or their metabolites capable of
forming covalent bonds with proteins.
Nevertheless, an additional positive factor
ofmacromolecule adducts measurement is
that they may be also considered biomark-
ers of effect when a similar chemical step
is involved in the pathogenesis of neuro-
toxicity, as shown below for n-hexane.
A number ofbiochemical measurements
relate to biological effects of neurotoxic
chemicals. However, as they do not directly
relate to neurotoxicity, they may be
considered biomarkers of exposure rather
than biomarkers of effect. In the case of
lead, for example, erythrocyte 6-aminole-
vulinic acid dehydratase (ALAD), which is
inhibited by this metal, is a widely used
biomarker; however, because of wide
interindividual variability, it may not be
well suited for lead exposure at or below'
lead levels of 10 pg/dl, which have been
associated with behavioral dysfunction
(24,25). Elevated zinc protoporphyrin
(ZZP) or the ZZP/hemoglobin ratio is also
well correlated with blood lead level but
only at concentrations higher than 40
pg/dl (26). Caution should be exerted
when using these biomarkers, as their
alterations may be associated with the
nutritional state ofthe organism, e.g., iron
deficiency (27). The interaction of neuro-
toxic metals, particularly lead and mercury,
with the heme biosynthetic pathway has
also been exploited to measure concentra-
tions of porphyrins in urine (26). Since
different metals inhibit this pathway at dif-
ferent steps, it is possible to fingerprint
exposure to a specific metal based on the
urinary porphyrin profile (26,28,29). These
measurements reflect biological effects of
metals but are not related to their known
mechanisms ofneurotoxicity. Nevertheless,
they represent additional means to assess
exposure to neurotoxic metals. For example,
urinary porphyrin changes in dentists
exposed to low-level mercury vapors have
been found to be a useful measure ofcumu-
lative effects ofmercury on specific tests of
neurobehavioral function (30,31).
Biomarkers ofEffect
Biomarkers of effect should reflect early
biochemical modifications that precede
structural or functional damage. Thus,
knowledge of the mechanism(s) that lead
to ultimate toxicity is necessary or at least
extremely important to develop specific
and useful biomarkers. Such markers
should identify early and reversible bio-
chemical events that may also be predictive
oflater responses (20). Unfortunately, the
exact mechanism ofaction for most neuro-
toxic chemicals is still unknown, a major
factor in the slow progress of biomarker
research in this area. Furthermore, finding
sensitive and specific surrogate markers for
the central and peripheral nervous system in
readily accessible tissues can be problematic.
Because of the complexity of the nervous
system and the diversity of manifestations
of neurotoxicity, together with the multi-
plicity ofcellular and biochemical targets
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for many chemicals, it is highly unlikely
that generic markers for neurotoxicity will
be developed. The problem is therefore dif-
ferent from that encountered with geno-
toxic compounds in which, for example,
changes in sister chromatide exchange in
circulating lymphocytes may reflect a sig-
nificant biological effect common to many
chemicals. It is therefore a situation not
dissimilar from that ofthe development of
in vitro assays for neurotoxicants, where it
is unlikely that a test such as the Ames test
will ever exist. Despite these obvious limi-
tations, different strategies have been
employed over the years in the attempt to
develop peripheral biochemical indicators
ofneurotoxicity.
One area of investigation that has
received some attention is that of neuro-
transmission. Several chemicals affect vari-
ous steps of neurotransmission, including
neurotransmitter metabolism, receptor
interactions, second messenger systems, or
other relevant enzymes (e.g., ATPase)
(14,32,33). As changes due to neurotoxi-
cant exposure cannot be measured in target
tissue, suitable peripheral cell systems must
be identified that can mirror identical neu-
rochemical parameters in the nervous sys-
tem. Cell types that have been used include
platelets, erythrocytes, lymphocytes, and
fibroblasts (4,34), and this strategy has
found applications in the field ofbiological
psychiatry and asthma research (15). The
oldest and probably still the best example
of the application ofsuch strategy to neu-
rotoxic compounds is represented by the
measurement of red blood cell acetyl-
cholinesterase following exposure to
organophosphorus insecticides. This and
other examples ofthis approach for some
neurotoxic chemicals are discussed in fol-
lowing sections. The development ofsuch
markers should follow the usual steps of
characterization and validation. It is neces-
sary to determine whether the particular
enzyme or receptor studied in blood cells is
indeed the same entity present in the ner-
vous system and whether it is similarly
affected in vitro by a neurotoxicant.
Animal studies should then be carried out
to investigate whether a good correlation
exists between changes in the peripheral
markers and those observed in the nervous
system; dose-response and time-course
studies should be included to assess sensi-
tivity ofmeasurements, and the duration of
the observed changes. Pilot studies in
humans should determine interindividual
variations as well as sensitivity upon expo-
sure to occupationally and environmentally
relevant concentrations. In addition to this
background work, one should also consider
limitations and pitfalls of this approach.
For example, does the change in a neuro-
transmitter metabolite reflect a primary
effect in the central or peripheral nervous
system? What other endogenous or exoge-
nous agents (hormones, drugs), pathologi-
cal conditions, or genetic makeup can affect
the measured parameters? Would falsely
positive results be obtained for compounds
that do not cross the blood-brain barrier?
Additional approaches to develop
biomarkers for neurotoxicity have recently
been proposed. Animal studies have shown
that levels of the astrocyte-specific glial
fibrillary acidic protein (GFAP) increase
following neuronal damage, and this
biochemical measurement has acquired
notable importance as an indicator ofneu-
rotoxicity (35). Though questions still
remain on the application of these mea-
surements to humans, it has recently been
reported that blood GFAP antibody levels
are significantly elevated in workers
exposed to lead (36). Still, it is unclear
whether this finding is related to a damage
of the blood-brain barrier rather than a
biomarker of neuronal damage. Indeed,
levels of another protein, creatine kinase
isoenzyme BB (CK-BB) were found to be
increased in the blood ofboxers and head
trauma patients (37,38). Since levels of
CK-BB are very low in control individuals,
this increase may indicate disruption ofthe
blood-brain barrier. The cerebrospinal fluid
(CSF) is another compartment that may be
accessible in humans. A very recent study
has reported the appearance ofmyelin basic
protein (MBP) in CSF of rats following
intracerebellar injection oflysolecithin (39).
As this treatment causes extensive demyeli-
nation, the increase ofMBP in CSF, which
lasted for about 4 days, may represent a
useful marker for this effect.
Biomarers ofSusceptibility
Though the importance ofgenetic factors
in the response to neurotoxic chemicals has
often been recognized, it has not received
much attention in the design ofneurotoxi-
cological studies (40). Most animal studies
use only a single strain of mice or rats so
that genetic variations in response are not
noted; however, several studies have shown
strain differences among laboratory animals
in response to a wide range ofxenobiotics
including neurotoxic agents. For example,
strain differences in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) neuro-
toxicity in mice have been reported and
have been associated with differences in
melanin binding or monoamine oxidase
activity (40,41). Genetic influences in the
developmental neurotoxicity ofalcohol are
also apparent (42). In humans, interindivid-
ual variations in response to drugs and other
xenobiotics are widely observed. The studies
ofsuch genetic variability in drug response
have been carried out for decades in the field
ofpharmacogenetics, while applications to
environmental chemicals in the field ofeco-
genetics have been investigated in the past
15 years (43-45).
Genetic polymorphisms have been iden-
tified for a number ofenzymes involved in
xenobiotic metabolism, in particular sev-
eral members of the cytochrome P450
(CYP), glutathione transferase (GST), and
N-acetyltransferase (NAT) families [see
recent reviews (46,47)]. A large number of
studies have revealed associations between
a certain genotype and increased risk for
smoking- or other xenobiotic-related
cancers. For example, mutants ofCYPlAl
and GSTM1 have been associated with an
increased incidence of lung cancer, and
slow acetylators (NAT 2 mutants) have
an increased risk for bladder cancer.
Presumably, these individuals have an
increased capacity of bioactivating and a
reduced capacity of detoxifying polycyclic
aromatic hydrocarbons, or they have a
decreased ability to detoxify arylamines.
Genetic polymorphisms have also been
identified for other enzymes involved in
xenobiotic metabolism, such as epoxide
hydrolase, alcohol and aldehyde dehydro-
genases, various esterases, and methyl-
transferases (46).
Organic neurotoxic compounds can be
bioactivated or detoxified by these same
enzymes, and genetic polymorphism could
certainly play a role in differential sensitiv-
ity to their effects on the central and
peripheral nervous systems. With very few
exceptions, biomarkers of susceptibility
have not been investigated with regard to
neurotoxicants. Yet, these may be ofgreat
importance where low exposures leading to
subtle behavioral effects are investigated.
Furthermore, in addition to their major
hepatic localization, several ofthese enzymes
are also expressed in the nervous system
(48) where they may contribute to in situ
activation ordetoxication ofneurotoxicants.
Some research on genetic polymor-
phism has been carried out in the context
ofstudies on the role ofenvironmental fac-
tors in the etiology of neurodegenerative
diseases such as Parkinson's disease. The
hypothesis underlying these studies is that
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genetically determined metabolic differ-
ences may contribute to an increased risk
for Parkinson's disease as a result ofexpo-
sure to still unidentified environmental
neurotoxic agents. Since MPTP, a toxicant
known to cause Parkinson's-like symp-
toms, needs to be bioactivated by mono-
amine oxidase B (MAO B), a few studies
have sought to determine whether poly-
morphisms ofMAO B (49) are involved in
Parkinson's disease. Kurth et al. (50) iden-
tified a single-stranded conformational
polymorphism in intron 13 ofthe MAO B
gene and found that one allele occurred
with a significantly higher frequency in
Parkinson's patients than in controls. This
finding, however, was not replicated in
another study (51). A decade ago it was
suggested that impaired debrisoquine
hydroxylation (which is due to CYP2D6)
was a genetic susceptibility factor for
Parkinson's disease (52), and this has been
confirmed in several, though not all,
studies (53-55). Though the Parkinson's-
causing neurotoxicants that may be metab-
olized by CP2D6 have not been identified
yet, some animal evidence seems to sup-
port the hypothesis that debrisoquine-poor
metabolizers are at risk for Parkinson's dis-
ease. For example, the metabolism of
tetraisoquinoline, a possible parkinsonism-
inducing substance, is significantly lower in
Dark Agouti rats (an animal model ofpoor
debrisoquine metabolizers) than in controls
(56). Additionally nicotine, which has
been consistantly found to be a protective
factor in Parkinson's disease, has been
shown to selectively induce cytochrome
P450s in rat brain without affecting their
expression in liver (57). Clearly, additonal
hypothesis-driven mechanistic investiga-
tions will strenghten the observations made
in epidemiological studies with regard to
the role ofthese and other polymorphisms
in Parkinson's disease and other neurode-
generative disorders.
Genetic polymorphisms in enzymes not
associated with xenobiotic metabolism but
involved in the metabolism ofendogenous
neurotransmitters (e.g., catechol-o-methyl-
transferase) may also affect the response to
certain neurotoxicants. Similarly, genetic
variations in receptors or other enzymes
involved in cellular functions, including
repair mechanisms, may be relevant to fully
predict and assess neuro-toxic outcome.
Although information in these areas is still
scant, it will certainly increase as the
knowledge of the human genome pro-
gresses and it will certainly offer new tools
for investigation.
Organophosphorus Insecticides
Organophosphorus compounds are still
among the most widely used insecticides.
Organophosphates were developed in the
1940s; their mechanism ofaction was read-
ily identified as inhibition of acetyl-
cholinesterase (AChE), which leads to
accumulation ofacetylcholine at choliner-
gic synapses with an ensuing cholinergic
crisis (58). Because of the role of acetyl-
choline as a neurotransmitter in both the
central and peripheral nervous systems,
AChE is widely distributed throughout the
body, including blood cells such as ery-
throcytes and lymphocytes. However, the
physiological role ofacetylcholinesterase in
these peripheral cells, which are devoid of
synaptic contacts, as well as of pseudo-
cholinesterase in plasma, have not been
elucidated. Nevertheless, because inhibi-
tion ofthese enzymes in blood also occurs,
measurement of their activities has been
extensively used as a biomarker ofexposure
to and effect oforganophosphates (59,60).
When used as a marker of exposure in
population studies, the issue of interper-
sonal variability should be carefully consid-
ered. When possible, baseline values should
be obtained for each individual, and varia-
tions below these activity levels rather than
absolute levels should be used to assess
exposure. In the absence of preexposure
measurements, repeated postexposure mea-
surements should be obtained at different
intervals. In this case a significant increase
in cholinesterase activity over time would
indicate recovery from an initial exposure
to an organophosphate (61). A much
debated issue is whether red blood cell
AChE or plasma cholinesterase is a better
indicator ofexposure to organophosphates.
Many organophosphates appear to be bet-
ter inhibitors ofcholinesterase, suggesting
that this enzyme may be a more sensitive
indicator ofexposure; however, this is not
true for all organophosphorus compounds.
Furthermore, plasma cholinesterase activ-
ity displays a higher variability because it
can be affected by other exogenous agents
(e.g., drugs) or physiological and patho-
logical conditions (e.g., pregnancy or liver
damage) (62). In addition, genetic variants
ofhuman serum cholinesterase exist (63).
Individuals with atypical cholinesterase,
which occurs in homozygous form in 1
out of 3,500 Caucasians and consists of a
single aminoacid substitution in position
70 (glycine instead of aspartic acid), have
an a abnormal response to the muscle
relaxant succinylcholine (63). Whether
genetic variants ofcholinesterase affect the
sensitivity to organophosphates remains to
be determined.
If blood cholinesterase activity is
considered a biomarker ofeffect oforgano-
phosphates, it is important to determine
whether this peripheral measurement
reflects similar changes occurring in target
tissues, i.e., the central nervous system and
the muscles, particularly the diaphragm.
Surprisingly, very few studies have directly
attempted to address this important ques-
tion, though those that did concluded that
blood cholinesterase is a good indicator of
target organ enzyme activity (64-66).
Erythrocyte AChE, in particular, was found
to be better correlated with brain or
diaphragm activity than plasma cholin-
esterase. This was observed, for example, in
animals exposed to different single doses of
the insecticide chlorpyrifos and paraoxon at
different times after dosing (66). During
repeated exposures to the insecticide disul-
foton, the strongest correlation was seen
between brain and lymphocyte AChE
activity (65); however, in the recovery
period following termination ofexposure,
red blood cell AChE better reflected brain
AChE activity. To strengthen these find-
ings, it is important to conduct additional
studies comparing blood and target tissue
AChE under various exposure conditions.
In particular, several different organophos-
phates should be tested, possibly at low
doses for extended periods of time, to
mimic occupational exposure. Nevertheless,
measurement of blood AChE activity
remains an excellent biomarker for exposure
and effect of organophosphate exposure
under both acute and chronic conditions.
Upon repeated exposure to organophos-
phates, tolerance to their toxicity has been
shown to develop (67). This tolerance is
mediated, at least in part, by a homeostatic
change in cholinergic receptors whose den-
sity decreases to compensate for the pro-
longed increase in acetylcholine levels
(68,69). These changes in cholinergic
receptors, particularly the muscarinic type,
may be seen as a protective mechanism by
which the organism normalizes function
despite challenge from the external envi-
ronment. On the other hand, balance of
neuronal connections may have been
altered, and higher brain functions might
be compromised by such receptor alter-
ations. Indeed, in animals repeatedly
exposed to the organophosphates disulfo-
ton or diisopropylfluorophosphate, mem-
ory deficits have been reported (70,71). As
such cognitive impairment was also
observed in some, but not all, studies of
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occupationally exposed workers (72,73), a
series of experiments were designed to
investigate whether a peripheral biomarker
of muscarinic receptors could be found
that would reflect changes in.central
nervous system muscarinic receptors.
Lymphocytes were considered as possible
surrogate tissue because in these cells from
rats and humans, muscarinic receptors have
been identified at the protein and mRNA
levels (74-76). Following a 2-week expo-
sure to the organophosphate disulfoton,
the density of muscarinic receptors was
decreased to a similar degree in hippocam-
pus and cerebral cortex as well as in circu-
lating lymphocytes (77). A more detailed
time-course studyindicated a strong corre-
lation between the levels of muscarinic
receptors in brain areas and lymphocytes
during the period of exposure (65).
However, in the recovery period following
termination ofexposure, such correlation
was not present, possibly because of the
high turnover oflymphocytes. Thus, mea-
surement oflymphocytic muscarinic recep-
tors should be seen as a useful indicator of
central nervous system changes onlyduring
prolonged exposure but not afterward.
A number of organophosphates also
cause another type ofneurotoxicity, char-
acterized as a central-peripheral distal
axonopathy (78,79). This syndrome, com-
monly known as organophosphate induced
delayed polyneuropathy (OPIDP), is
totally independent ofinhibition ofAChE
and is delayed as symptoms appear about 2
to 3 weeks after the initial poisoning when
acute cholinergic signs have subsided. The
mechanism of initiation of OPIDP
involves the phosphorylation of a protein
in the nervous system called neuropathy
target esterase (NTE) and the aging of
the phosphoryl-enzyme complex (80).
Compounds that age cause OPIDP ifthe
threshold ofinhibition ofNTE (70-80%)
is reached, whereas compounds that do not
age (e.g., phosphinates or carbamates) do
not cause OPIDP and, when given before a
neuropathic compound, actually protect
against its delayed neurotoxicity. NTE
activity has been found in lymphocytes and
platelets (81,82). Within 24 hr after acute
exposure, there is a good correlation
between lymphocyte and brain NTE in the
hen, which is the species of choice for
OPIDP studies (83). Measurement of
lymphocyte NTE has been suggested as
a potential biomarker to monitor for
organophosphate-induced polyneuropathy
(84). The best example of its application
in humans is in a case report of an
attempted suicide with the insecticide
chlorpyrifos in which, based on 60% inhi-
bition oflymphocyte NTE, itwas correctly
predicted that a neuropathy would develop
well after recovery from acute cholinergic
poisoning had occurred (85). In a study of
workers exposed to the defoliant DEF,
inhibition of lymphocyte NTE was
observed but was considered a false positive
because no clinical or electrophysiological
signs of OPIDP were detected in exposed
workers (86). Recently, compounds that
offer protection when given before a neuro-
pathic organophosphate have been found to
act as promoters (i.e., to potentiate OPIDP)
when given afterward (87). These findings
have challenged the understanding ofthe
mechanisms ofOPIDP and, unfortunately,
complicated the use oflymphocyte NTE as
a biomarker, as the clinical outcome ofa
combined exposure to protective/promoter
and neuropathic pesticides would be
unpredictable (79).
The metabolism oforganophosphates
offers the possibility ofinvestigating possi-
ble polymorphisms ofmetabolic enzymes
as biomarkers ofsusceptibility and ofmea-
suring metabolites in the urine as biomark-
ers of exposure. Most organophosphates
are activated to their correspective oxygen
analog by an oxidative desulfuration reac-
tion, which is catalyzed by cytochrome
P450. Upon phosphorylation ofAChE, a
portion ofthe molecule, the leaving group,
is released and excreted. Both the parent
compound and the oxon can undergo a
series ofdetoxication reactions that are
mediated by various A esterases (paraox-
onase, carboxyesterase), by P450s, and by
glutathione transferases. The leaving group,
p-nitrophenol in the case of parathion,
which is also generated by hydrolytic cleav-
age, and alkylphosphates are excreted in the
urine and can be quantified as an index of
organophosphate exposure (88-90). In the
case ofalkylphosphates, studies in humans
have indicated that they may represent a
sensitive marker oforganophosphate expo-
sure because theymaybe detected even ifno
significant changes in blood cholinesterase
activity can be measured (91).
Because ofthe importance ofthe acti-
vation step in the toxicity oforganophos-
phates, genetically determined differences
in cytochrome P450 may play a significant
role. Though the need ofthe conversion to
the oxon has been known for almost 40
years (58), the specific P450 isozyme(s)
responsible for the activation ofthioates
has not, to my knowledge, been identified.
The same is truewith regard to glutathione
transferases, whose role in the detoxication
of organophosphates (particularly the
methyl substituted) is still controversial
(92). Clearly, genetic variations in these
enzymes may be important, especially to
explain the exacerbated reactions to
organophosphate exposure observed in cer-
tain individuals. This is certainly an area
where some additional research efforts
should be addressed.
A metabolic pathway that has been
investigated in this context is the hydrolysis
of several organophosphates by paraox-
onase. This enzyme, which takes its name
from its most studied substrate, paraoxon,
is capable of hydrolyzing the oxygen
analogs of a number of commonly used
organophosphorus insecticides such as
chlorpyrifos oxon and diazinon oxon. It
has been long known that human paraox-
onase exhibits a substrate-dependent poly-
morphism (93). One form hydrolyzes
paraoxon with a high turnover number,
and the other form with a low turnover
number (94,95). In addition to the
observed polymorphism, there is a large
variation in enzyme levels (over 10-fold)
observed within a genetic class, with a full
scale variation of about 60-fold (94).
Several lines ofevidence suggest that high
levels ofserum paraoxonase are protective
against poisoning by organophosphorus
insecticides whose active metabolites are
substrates of this enzyme. Birds, which
have very low levels ofserum paraoxonase,
are very sensitive to diazinon oxon, pirim-
iphos oxon, or parathion compared to
mammals (96,97). Rabbits, which have a
very high level ofserum paraoxonase, are
less sensitive than rats to the acute toxicity
ofparaoxon (98). Furthermore, when rats
or mice are injected with paraoxonase puri-
fied from rabbit serum to increase the
blood hydrolyzing activity, their sensitivity
toward the toxicity ofparaoxon and chlor-
pyrifos oxon is significantly decreased
(99-101). Interestingly, administration of
exogenous paraoxonase to mice also offers
protection against the toxicity ofthe parent
compound chlorpyrifos (102). These ani-
mal experiments provide convincing evi-
dence that serum paraoxonase is an
important determinant ofsusceptibility to
organophosphate poisoning.
The polymorphism ofhuman paraox-
onase has been recently elucidated. One
isoform, with arginine at position 192,
hydrolyzes paraoxon with a high rate,
whereas the other isoform, with glutamine
at position 192, hydrolyzes paraoxon at a
slower rate (103). In population studies,
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three genotypes have been observed: indi-
viduals homozygous for the low activity
allele (48%), individuals homozygous for
the high activity allele (9%), and heterozy-
gotes (43%) (94). Because not all sub-
strates exhibit polymorphism and because
ofthe large variability ofexpression, certain
considerations should be made about the
use of paraoxonase status as a genetic
marker for susceptibility to poisoning by
organophosphates. For example, an indi-
vidual who is homozygous for the low-
activity allele and also has very low levels of
the Gln192 protein would be expected to
hydrolyze both paraoxon and chlorpyrifos
oxon very slowly and would be predicted to
be sensitive to both compounds. However,
an individual who has veryhigh levels ofthe
Gln192 isoform would be able to hydrolyze
chlorpyrifos oxon very rapidly but, due to
the genetic polymorphism (i.e., Gln instead
ofArg at position 192), would still be a
relatively low metabolizer ofparaoxon.
Styrene
Styrene is a very important solvent used in
the manufacture of numerous polymers
and copolymers including polystyrene,
styrene-acrylonitrile, and styrene-buta-
diene rubber (104). As for other organic
solvents, acute exposure to high levels of
styrene causes irritation (of both skin and
respiratory tract) and central nervous sys-
tem depression (105). Upon chronic expo-
sure, styrene may have carcinogenic and
reproductive toxicity (105,106). In vitro
studies suggest that the metabolite styrene
oxide may mediate genotoxic and develop-
mental toxic effect of styrene (107,108).
Styrene exposure has also been reported to
cause neurotoxic effects. Indeed, a large
number ofstudies involving occupationally
exposed workers have reported signs and
symptoms ofcentral nervous system toxic-
ity (109-114), though a recent review has
challenged several ofthese findings (115).
Because of the widespread use of
styrene, its biological monitoring has
been extensively investigated (116).
Styrene is metabolized to styrene oxide by
cytochrome P450s; styrene oxide is then
detoxified via glutathione transferases
and/or epoxide hydrolase, the latter path-
way being more significant in humans than
in rodents (117). Mandelic acid and
phenylglyoxylic acid are the most promi-
nent metabolites found in urine (117).
Styrene in blood, urine, and exhaled air, as
well as urinary mandelic acid and phenyl-
glyoxylic acid, have been commonly used
for biological monitoring (116-119).
Threefold differences in the relative urinary
excretion of optical enantiomers of man-
delic acid have been reported and have
been suggested to be related to polymor-
phisms of cytochrome P450s, leading to
R- or S- styrene 7,8-oxide or epoxide
hydrolase (120). This observation may be
relevant with regard to genotoxicity as
R-styrene 7,8-oxide has a stronger muta-
genic effect than its S enantiomer (121).
Styrene oxide can form adducts to the
N-valine residue on hemoglobin (122-124),
and measurement of these adducts has
been used to monitor exposure to styrene
in animals and humans (125-127). How-
ever, styrene oxide is not considered an
effective alkylator ofhemoglobin compared
to other toxicants such as ethylene oxide
(128). Furthermore, the capacity ofhumans
to form styrene oxide is much lower than
rats or mice (117); thus, very low levels of
styrene oxide (129) and styrene oxide-
hemoglobin adducts (125,126) are found in
human blood.
While these measurements can be used
as biomarkers of styrene exposure, none
appear to be mechanistically linked to the
neurotoxicity ofstyrene. In fact, the spe-
cific neurotoxic targets for styrene, its
mechanism(s) of neurotoxicity, and the
role played by styrene oxide are for the
most part still unknown. Exposure ofrats
to styrene has been shown to decrease lev-
els ofbrain glutathione (130,131), and this
effect has been attributed for the most part
to detoxication of styrene oxide by glu-
tathione transferases (132). Following
chronic exposure to styrene, an increase in
GFAP was found, possibly reflecting reac-
tive astrogliosis to styrene- or styrene
oxide-induced neuronal damage (133). An
in vitro study in PC12 cells has indeed
shown that styrene oxide causes depletion
of intracellular glutathione and ATP,
followed by elevation offree calcium levels
and induction ofDNA single strand breaks
(107). A more recent study in primary cul-
tures of murine spinal cord-dorsal root
ganglia indicated cytotoxicity of styrene
and styrene oxide (the latter being about
10-fold more potent), and oxidation of
multiple cellular macromolecules was sug-
gested as a mechanism oftoxicity (134). A
number of animal studies have suggested
that styrene can affect the metabolism of
dopamine. An increase in dopamine D2
receptors has been found in rats following
adult and developmental exposure to
styrene (135,136). This increase may be a
compensatory reaction to the observed
decrease in dopamine levels (137), which
has been ascribed to condensation of
dopamine with the styrene metabolite
phenylglyoxylic acid (138). These findings
were mechanistically correlated with an
increase in prolactin levels found in the
blood ofstyrene-exposed workers, as pro-
lactin release from the anterior pituitary
gland is chronically inhibited by dopamine
(139-141). Although of interest, this
hypothesis should be viewed with caution,
and further evidence should be provided in
its support. A decrease in MAO B was
found in the brain of rats exposed to
styrene (142). A dose-related decrease of
MAO B activity has also been found in
three separate studies of platelets from
workers exposed to styrene (114,141,142).
The effect appeared to be specific for
styrene, as it was not observed in plate-
lets ofworkers exposed to the solvents
perchloroethylene and toluene (143,144).
On the other hand, a decrease in serum
dopamine-p-hydroxylase (DBH) activity
was found in workers exposed to both
styrene and toluene (141,144), possibly
because ofinhibition ofits activity by phe-
nol/cresol metabolites ofthese solvents, but
not following exposure to trichloroethylene
(145). Overall, these observations are of
interest because they may lead to effect-
related biomarkers for styrene. However, a
better understanding ofthe mechanism of
styrene (and/or styrene oxide) neurotoxic-
ity is necessary before these and other
biomarkers can be used with confidence.
n-Hexane
The neurotoxicity of n-hexane was first
identified in humans and then confirmed
by animal studies. Symptoms of n-hexane
neurotoxicity are numbness ofthe extremi-
ties followed by weakness of the intrinsic
muscles of the hands and feet and, with
continuous exposure, progressive loss of
sensory and motor functions. Observations
in humans and investigations in animals
have characterized this as a distal sensori-
motor neuropathy, specifically a distal
axonopathy (dying-back) type (146).
Another solvent, methyl n-butyl ketone,
also causes a sensorimotor neuropathy, and
the formation ofthe same toxic metabolite,
2,5-hexanedione, from both n-hexane and
methyl n-butyl ketone has been firmly
demonstrated (147). The pathogenesis of
n-hexane neuropathy has been recently
reviewed (148). The reaction of2,5-hexa-
nedione (and other y-diketones, but not
diketones with other than y-spacing) with
the lysyl groups ofproteins leads via a series
of intermediate steps to the formation of
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chemical adducts characterized as pyrroles
(149,150). Experiments with diastereoiso-
mers of3,4-dimethyl-2,5-hexanedione have
indicated that the formation ofthe pyrrole
is a critical step in the sequence ofevents
that result in the axonopathy (151). Further
experiments have also shown that, though
formation ofpyrrole is a necessary step in
neurotoxicity, it is not sufficient because
pyrrole oxidation must also occur, leading
to neurofilament cross-linking (152).
Exposure to n-hexane in occupationally
exposed workers has been mostly assessed
by determination of urinary levels of
the toxic metabolite 2,5-hexanedione
(153,154). However, this measurement
reflects only recent exposure, in the order
ofa few hours to a few days. On the other
hand, the mechanistic studies summarized
above offer the possibility of using mea-
surement of pyrrole adducts to macro-
molecules as a biomarker of cumulative
exposure to n-hexane. Experiments in rats
exposed to y-diketones have shown that
formation ofhemoglobin adducts is pro-
portional to both time and dose (155). As
the formation ofadducts has been shown
to be causally related to the development of
neuropathy, hemoglobin may be seen as a
surrogate for neurofilaments during in vivo
exposure (148). As such, measurements of
hemoglobin pyrrole adducts in the case of
n-hexane are more than a biomarker of
exposure and can be seen as a biomarker
of effect. In this regard, more detailed
dose-response studies in animals, as well as
studies in humans, may be useful to arrive
at a better quantitative assessment of neu-
rotoxic risk linked to exposure to n-hexane
or othery-diketone precursors.
As the cross-linking ofneurofilaments
is essential for neurofilament-filled axonal
swellings (148), the ability to measure
protein cross-linking in an accessible tissue
would provide an additional means of
assessing exposure to and health effects of
n-hexane. A protein present in erythro-
cytes, spectrin, has proved to be useful in
this regard. The a and 0 subunits ofspec-
trin are closely associated on the cytoplas-
mic side ofthe red blood cell membrane.
Cross-linking compounds yield a, P-het-
erodimers that can be identified in SDS
polyacrylamide gels (148). Neurotoxic
y-diketones have been indeed shown to
cause spectrin dimerization, while adminis-
tration of nontoxic diketones does not
cause spectrin cross-linking (151,152,156).
This biochemical change, which also has
been observed following exposure to carbon
disulfide, may serve even more than pyrrole
adducts as a biomarker directly related to
pathological changes in the axon. Its inves-
tigation in animals and humans exposed
to other peripheral neurotoxicants is cer-
tainly warranted as long as the underlying
mechanisms are carefully considered.
CarbonDisulfide
Exposure to carbon disulfide (CS2) also
results in neurotoxicity. The most common
effect is a distal sensorimotor neuropathy
characterized as a neurofilamentous axono-
pathy (157). Despite the chemical dissimi-
larity between CS2 and n-hexane, both
compounds cause identical neuropathies
(148). Differently from n-hexane, chronic
exposure to CS2 has also been associated
with the development ofan encephalopathy
(158) whose mechanism has not been elu-
cidated. The pathogenesis of CS2 periph-
eral neuropathy has also been recently
reviewed (148). Though CS2 does not
form pyrrole adducts, through a series of
interactions with amino groups ofproteins,
it ultimately causes neurofilament cross-
linking. CS2 combines with primary and
secondary amines to generate dithiocarba-
mates, which are converted to isothio-
cyanate adducts. The latter may undergo
nucleophilic addition ofsulfydryl or amine
groups, creating dithiocarbamate ester and
thiourea covalent bridges, respectively
(148), and the thiourea cross-link appears
to be irreversible. These mechanistic studies,
and others that have shown the ability of
CS2 to cause cross-linking of proteins
(159), have led to another potential bio-
marker that may be useful in assessing the
peripheral neurotoxicity of CS2. As for
n-hexane, erythrocyte spectrin is cross-
linked by CS2, and the accumulation of
spectrin dimers in rats is proportional to
both time and dose (159). Even more
interestingly, spectrin dimers could be
detected before clinical or morphological
evidence for neurotoxicity (160). It has
also been shown that carbonyl sulfide,
which derives from oxidative metabolism
of CS2 by yet unidentified cytochrome
P450(s), can also participate in cross-linking
reactions via a protein-bound isocyanate
intermediate (148). The contribution of
carbonyl sulfide in the peripheral neurotox-
icity ofCS2 is not known, but in light of
possible polymorphisms of the P450(s)
involved in the oxidation ofCS2, it would
be ofinterest to define the relative roles of
the parent compound and this metabolite.
Concentration ofCS2 in expired air has
been used in the occupational setting as a
marker of exposure (161); however, this
measurement only reflects very recent
exposure. The reaction ofCS2 with amines
to yield dithiocarbamates has led to the
monitoring of the latter in blood as a
method to assess occupational exposure
(162). Furthermore, 2-thiothiazolidine-4-
carboxylic acid, a metabolite derived either
from dithiocarbamate or from trithiocar-
bonate, has been identified in urine from
workers exposed to CS2 and has been used
to monitor exposure (163,164); the cur-
rent biological exposure index is based on
such measurements (165).
As mentioned earlier, encephalopathy
is another manifestation ofthe neurotoxic-
ity of CS2 neurotoxicity. Animal studies
have shown that, in rats, brain dopamine
levels are increased following exposure to
CS2 (166), suggesting that, among various
possibilities, CS2 may inhibit DBH. This
biochemical effect has indeed been
observed in vitro (167), and in vivo in rat
adrenals following acute, but not chronic,
exposure (168,169). On the other hand,
in a group offemale viscose rayon workers
exposed to low levels ofCS2, a decrease in
serum DBH was observed only after pro-
longed exposure (more than 1 year) (170).
There are no studies, to my knowledge,
that have pursued the involvement of
alterations ofdopamine metabolism in the
central neurotoxicity ofCS2; thus, the sig-
nificance ofthese observations with regard
to possible use as biomarker is unknown.
Furthermore, the effects on peripheral
dopamine metabolism are probably impos-
sible to discern from those on the central
nervous system.
Acrqlamide
Acrylamide is an important chemical used
in the synthesis ofpolyacrylamides, which
have a variety of industrial applications.
Though various toxic effects ofacrylamide,
(e.g., reproductive toxicity and possibly car-
cinogenicity) have been suggested by ani-
mal studies (171), the most relevant effect
identified in humans is neurotoxicity, most
notably adistal axonopathy (172-174).
Earlier studies on the distribution of
14C-acrylamide in rats had indicated that a
high level of radioactivity was associated
with blood erythrocytes (175,176).
Hashimoto and Aldridge (175) also
observed in vitro studies in which acry-
lamide was covalently bound to cysteine
residues in brain proteins and hemoglobin,
and that, on acid hydrolysis, the formed
adduct yielded a compound identified as
S-(2-carboxyethyl) cysteine (CEC). Based
on this information, Bailey et al. (177)
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developed a gas chromatography-mass
spectrometry method to measure CEC in
hydrolyzed globin from acrylamide-treated
rats. These investigators reported a dose-
dependent increase in CEC for intravenous
doses ofacrylamide of0.1 to 5 mg/kg and
also noted the presence ofbackground lev-
els of CEC in untreated animals. In the
past few years, a series of studies have
extended these results to both animals and
exposed human populations. An initial
finding was the identification of a novel
adduct [S-2-(carboxy-2-hydroxyethyl)-cys-
teine] in hydrolyzed hemoglobin samples
from rats treated with acrylamide in vivo
and in microsomal suspensions of acry-
lamide with cysteine in vitro (178). The
presence ofthis adduct indicated the con-
version of acrylamide to glycidamide, a
reactive epoxide metabolite. In rats injected
with increasing doses (5-100 mg/kg) of
acrylamide or glycidamide, hemoglobin
adducts increased linearly (179), and on a
mole per kilogram basis, glycidamide
adducts were 3.2 times lower than acry-
lamide adducts. Following administration
of acrylamide, formation ofglycidamide
adduct generated a concave curve, presum-
ably reflecting the Michaelis-Menten kinet-
ics of its formation, and the percentage of
acrylamide converted to glycidamide was
inversely proportional to the dose (179).
Subchronic treatments of rats with acry-
lamide confirmed that the conversion rate
of acrylamide to glycidamide, as deter-
mined from hemoglobin adduct formation,
is higher at low administered doses (179).
Glycidamide may be involved in the
reproductive toxicity ofacrylamide (180)
and in its potential carcinogenicity because
this metabolite, but not the parent com-
pound, is mutagenic in the Ames test
(181). Uncertainties still exist, however,
on the role ofglycidamide in the patho-
genesis ofacrylamide-induced peripheral
neuropathy, since contrasting results have
been reported (182-185).
A method was also developed to deter-
mine acrylamide and glycidamide adducts
to N-terminal valine following total
hydrolysis and by means of the modified
Edman degradation procedure, which
was used to assess exposure to acrylamide
in a group of factory workers (186).
Adducts were detected in all exposed
workers (0.3-34 nmol/g Hb) and in only 1
out of 10 controls (0.01 nmol/g Hb).
Glycidamide adducts were determined in a
small subset ofexposed workers (1.6-32
nmol/g Hb) and were highly correlated
with acrylamide adducts. Based on their
roles and locations in the production
process, workers were divided into four
groups (186), and the highest adduct levels
(14.7 nmol/g Hb) were found in workers
involved in the synthesis of acrylamide
from acrylonitrile and in the transfer of
35% acrylamide solutions into barrels.
Based on extrapolations from air concen-
trations of acrylamide, it was calculated
that only a fraction of adducts (0.44
nmol/g Hb) would derive from inhalation
of acrylamide, indicating dermal absorp-
tion as a primary route ofexposure (187).
Among the exposed workers, signs and
symptoms indicating peripheral neuropa-
thy were found with statistically significant
increased frequencies compared to con-
trols. Based on the result of a question-
naire, a neurological examination, and
vibration thresholds and electroneuromyo-
graphic measurements, a neurotoxicity
index for acrylamide-induced peripheral
neuropathy was developed (187). The
neurotoxicity index, which adequately pre-
dicted the clinical diagnosis ofperipheral
neuropathy, was significantly correlated
with hemoglobin adducts of acrylamide
and with an accumulated in vivo dose of
acrylamide but not with the concentration
of acrylamide in the air or in plasma of
exposed workers. A good correlation was
also found between the neurotoxicity index
and hemoglobin adducts of acrylonitrile
(which is explained by a correlation
between acrylamide and acrylonitrile expo-
sure) and by mercapturic acid in the urine
(which could result from both acrylamide
and acrylonitrile) (187). Overall, these
studies indicate that measurement ofhemo-
globin adducts ofacrylamide is a good bio-
marker ofexposure and may be useful as an
indicator ofacrylamide-induced peripheral
neuropathy. Though the mechanism ofthe
peripheral neurotoxicity ofacrylamide has
not been fully elucidated, these studies sug-
gest that a covalent bond to axonal pro-
teins may present a relevant step in the
pathogenesis of its axonopathy. Further
studies may also lead to a better definition
ofthe dose-response relationship ofhemo-
globin adduct formation and their use as
predictors ofperipheral neurotoxicity.
Conclusions
In this brief review, I have discussed some
aspects of biomarker research as they
relates to the assessment of exposure and
susceptibility to and the effects of neuro-
toxic chemicals. By far, the best available
tools are in the area of biomarkers of
exposure; traditional measurements of
neurotoxic chemicals and their metabolites
in biological fluids provide useful and
reliable indicators of exposure. Novel
approaches such as measurements ofhemo-
globin adducts may be useful for assessing
prior and repeated exposures to elec-
trophilic compounds. For these chemicals,
further mechanistic studies should be car-
ried out, as the formation of adducts to
proteins in the target tissue may represent
an essential step in the pathogenesis of
neurotoxicity. Ifthis were the case (as dis-
cussed for n-hexane), measurements of
adducts in blood could also used as bio-
markers ofeffect. As several neurotoxicants
undergo metabolic activation or detoxifica-
tion by enzymes that are known to exhibit
polymorphisms in humans, it is surprising
that little attention has been devoted to
this topic within neurotoxicology. The
examples and suggestions provided may
serve to stimulate more research in this
area, which may be relevant in light ofthe
lower levels ofexposure normally encoun-
tered in developed countries. As techniques
for genotyping are becoming more accessi-
ble, epidemiological studies on occupation-
ally exposed workers may include such
measurements when proper hypothesis can
be formulated.
With regard to biomarkers ofeffect, it
is clear that new opportunities will derive
only from a better understanding of the
cellular and molecular targets for neurotox-
icants. Although these efforts may not ulti-
mately lead to useful reliable markers for
use in epidemiological studies, they will
certainly allow the testing ofmechanism-
driven hypotheses. In the few cases where
this has occurred (e.g., organophosphates),
useful biomarkers have indeed been devel-
oped. Clearly, neurotoxicity can be mani-
fested in a wide variety ofways, each one
characterized by different cellular and
biochemical substrates. Thus, the develop-
ment of one or more markers for neuro-
toxic effects does not appear as a feasible
option. Rather, biomarkers would be spe-
cific for a class ofchemicals or a target cel-
lular process (e.g., myelination). Still, by
understanding the chain ofevents that ulti-
mately lead to neurotoxicity, it is possible
to develop biomarkers that would be
indicative ofearly biochemical alterations
preceding irreversible damage. As neuro-
toxicology, possibly more than other areas
oftoxicology, requires a multidisciplinary
approach, the best use ofbiomarkers would
ultimately be in conjunction with electro-
physiological and behavioral assessments.
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